|
Below, you'll find more information on
asbestos lung cancer articles and products. Arm yourself with everything you need to know about asbestos lung cancer
Texas Mesothelioma Lawyers: Should You Seek Help From One?
By Wilmer
Texas mesothelioma lawyers can get you the compensation you deserve. Have you recently been diagnosed with mesothelioma? You should understand how dangerous mesothelioma is. In case you have no idea what mesothelioma is, then let us explain, it is a cancer that is caused by being exposed to asbestos fibers.
These fibers get into the protective covering of the lungs and affects the heart and abdomen and causes cancer. Texas mesothelioma lawyers can help you because manufacturing companies have known about the dangers of asbestos for more than 60 years. Since companies have been informed about this deadly disease, they definitely are responsible for your health.
How do you get good mesothelioma attorneys? As a mesothelioma victim, you will need to be represented by an excellent attorney who can get you as much money as possible. To find a good lawyer you should follow these tips.
Make sure the Texas Mesothelioma lawyers are legally licensed to practice in Texas and whether you are looking for a Beaumont mesothelioma attorney or a Dallas attorney; be sure to ask for experience with this particular issue! When you get this illness you need the best representation possible from a qualified attorney who can get you the right compensation and this is regardless of whether you are looking for a Beaumont mesothelioma attorney or a Dallas attorney. Visit more than one attorney and ask the same questions, so that you will be able to make a more informed decision.
Because you are a mesothelioma victim you need to ask for a lawyers qualifications, and you shouldn't be concerned about being embarrassed. Another great way of finding the right mesothelioma attorney is to ask your mesothelioma doctor if he can recommend an attorney. You might also be able to find a good
?Going Green? Against Skin Cancer
(Source: Pigment Cell Research)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Blood flow velocity imaging of malignant melanoma by micro multipoint laser Doppler velocimetry
In this study, we attempted to perform blood flow velocity imaging ... [Appl. Phys. Lett. 97, 103702 (2010)] published Tue Sep 7, 2010. (Source: Applied Physics Letters)
Comparative evaluation of NBUVB phototherapy and PUVA photochemotherapy in chronic plaque psoriasis
Conclusion: We concluded that PUVA group patients achieved a faster clearance, but the adverse effects were significantly lower in the NBUVB group. (Source: Indian Journal of Dermatology, Venereology and Leprology)
Autosomal dominant epidermodysplasia verruciformis: A clinicotherapeutic experience in two cases
Surbhi Vohra, Nand Lal Sharma, Vinay Shanker, Vikram K Mahajan, Nidhi JindalIndian Journal of Dermatology, Venereology, and Leprology 2010 76(5):557-561Epidermodysplasia verruciformis (EV) is a rare genodermatosis characterized by a unique susceptibility to cutaneous infection by a group of phylogenetically related human papilloma viruses (HPVs). These patients show a defect in cell-mediated immunity specific toward the causative HPVs that lead to lifelong disease. The defect is usually inherited as autosomal recessive trait and presents clinically with plane warts, pityriasis versicolor-like lesions and reddish verrucous plaques. Dysplastic and malignant changes in the form of actinic keratoses, Bowen's disease and squamous cell carcinoma (SCC) are common but metastasis occurs rare...
Bristol-Myers Squibb to Buy ZymoGenetics
The deal is about $885 million, Bristol said. (Source: NYT Health)
Rare victory in fight against melanoma
Patients with advanced melanoma rarely live for more than a year after their diagnosis--a prognosis that has not improved for more than 30 years. [More] (Source: Scientific American - Official RSS Feed)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Survival and quality of life of patients with oral and oropharyngeal cancer at 1-year follow-up of tumor resection
This study aimed to assess the survival and life quality evolution of patients subjected to surgical excision of oral and oropharyngeal squamous cell carcinoma. MATERIAL AND METHODS: Forty-seven patients treated at a Brazilian healthcare unit specialized in head and neck surgery between 2006 and 2007 were enrolled in the study. The gathering of data comprised reviewing hospital files and applying the University of Washington Quality of Life (UW-QOL) questionnaire previously and 1 year after the surgery. Comparative analysis used Poisson regression to assess factors associated with survival and a paired t-test to compare preoperative and 1-year postoperative QOL ratings. RESULTS: 1 year after surgery, 7 patients were not found (dropout of the cohort); 15 had died and 25 fulfilled the UW-QOL...
Promoter hypermethylation and expression profile of MGMT and CDH1 genes in oral cavity cancer
Conclusion: Our findings, for the first time, in a South-Eastern Iranian population, indicate that the two genes are aberrantly methylated in OSCC, and that MGMT methylation may be considered as a potential molecular marker for the poor survival in advanced OSCC. (Source: Archives of Oral Biology)
Hereditary Genodermatoses with Cancer Predisposition
In this article hereditary genodermatoses with cancer predisposition are reviewed, including nevoid basal cell carcinoma syndrome, neurofibromatosis types 1 and 2, tuberous sclerosis complex, xeroderma pigmentosum, and dyskeratosis congenita. Hereditary melanoma is also included, though it differs from the others in several respects. The underlying genetic aberrations causing these syndromes are largely known, allowing novel treatments to be developed for some of these disorders. Early recognition and diagnosis allows for close follow-up and surveillance for associated malignancies. (Source: Hematology/Oncology Clinics of North America)
Rare victory in fight against melanoma
Genetically tailored approach could slow disease progress. (Source: news@nature.com)
Rare victory in fight against melanoma
Genetically tailored approach could slow disease progress. (Source: news@nature.com)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
MicroRNA-7 targets insulin-like growth factor 1 receptor (IGF1R) in tongue squamous cell carcinoma cells
MicroRNA-7 (miR-7) has been characterized as a tumor suppresser in several human cancers. It targets a number of proto-oncogenes that contribute to cell proliferation and survival. However, the mechanism(s) by which miR-7 suppresses tumorigenesis in tongue squamous cell carcinoma (TSCC) is unknown. Our bioinformatics analysis revealed that the insulin-like growth factor 1 receptor (IGF1R) mRNA is a potential target for miR-7. Ectopic transfection of miR-7 led to significant reduction of IGF1R at both the mRNA and protein levels in the TSCC cells. Knockdown of miR-7 in the TSCC cells enhanced the IGF1R expression. Direct targeting of miR-7 to three candidate binding sequences located in the 3’-untranslated region of IGF1R mRNA was confirmed using luciferase reporter gene assays. The ...
Q & A: The Hair of My Chin
If I tweeze out the single hair that grows from a facial mole, will it cause cancer, as my friend insists? (Source: NYT Health)
Lymphoma occurring in patients with cutaneous melanoma
Conclusions
A small but significant proportion of patients with melanoma develop lymphoma, either synchronously or metachronously. Lymph node specimens from melanoma patients might harbour lymphoma, and might represent the first recognised site of disease. A high index of suspicion for lymphoma when evaluating lymph nodes from patients with melanoma will ensure prompt diagnosis and appropriate management. (Source: Journal of Clinical Pathology)
AP1 factor inactivation in the suprabasal epidermis causes increased epidermal hyperproliferation and hyperkeratosis but reduced carcinogen-dependent tumor formation
Authors: E A Rorke, G Adhikary, R Jans, J F Crish
& R L Eckert (Source: Oncogene)
Hyperactivation of MEK?ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells
Oncogene advance online publication, September 6, 2010. doi:10.1038/onc.2010.408
Authors: F M Kaplan, Y Shao, M M Mayberry
& A E Aplin (Source: Oncogene)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Midkine expression is correlated with an adverse prognosis and is down-regulated by p53 in oral squamous cell carcinoma.
Authors: Ota K, Fujimori H, Ueda M, Jono H, Shinriki S, Ota T, Sueyoshi T, Taura M, Taguma A, Kai H, Shinohara M, Ando Y
Midkine (MK) expression has been documented to be inversely correlated with the prognosis of patients with various tumors, but the mechanism of this relationship has not been well characterized. Recent studies have also correlated p53 expression with prognosis of patients with oral squamous cell carcinoma (OSCC). We evaluated the relationship between MK expression and clinicopathological features of patients with OSCC to clarify the influence of p53 status on MK expression in OSCC cells. Our results showed that patients with MK over-expression in OSCC cells had a significantly lower 5-year survival rate compared with patients with low MK expression. Immunohistochemic...
Acacia honey and chrysin reduce proliferation of melanoma cells through alterations in cell cycle progression.
In this study, we investigated the antiproliferative role of honey or chrysin on human (A375) and murine (B16-F1) melanoma cell lines. The results of the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and the trypan blue exclusion test showed that both the tested compounds were able to induce an antiproliferative effect on melanoma cells in a dose- and time-dependent manner. Flow cytometry analysis indicated that cytotoxicity induced by honey or chrysin was mediated by G0/G1 cell cycle arrest and induction of hyperploid progression. Our results suggest that the anti-proliferative effects of honey are due mainly to the presence of chrysin. Chrysin may therefore be considered a potential candidate for both cancer prevention and treatment. Further investigation is n...
2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Authors: Li CM, Narayanan R, Lu Y, Hurh E, Coss CC, Barrett CM, Miller DD, Dalton JT
Phosphatidylinositol-3-kinase (PI3K)/Akt and 5'-AMP-activated protein kinase (AMPK) are attractive targets for anti-cancer drug development. Inhibition of Akt or activation of AMPK is cytotoxic to human cancer cells in vitro and in vivo. We previously demonstrated that 2-arylthiazolidine-4-carboxylic acid amides (ATCAA) are effective cytotoxic agents in prostate and melanoma cancer cell lines, with IC50 values in the low/sub micromolar range. Using in vitro and in vivo studies, we further characterized the anti-cancer efficacy and mechanism of action of ATCAA-10, a potent lead. ATCAA-10 exhibited equal potency on both MES/SA and P-glycoprotein over-expressing multidrug resistant MES/SA/Dx5 cells, sugge...
Chemical In Widely Consumed Foods Linked To Skin Cancer
The September cover story of the nation's leading cancer journal, Cancer Research, features a new study from The Hormel Institute, University of Minnesota, that links capsaicin, a component of chili peppers, to skin cancer. While the molecular mechanisms of the cancer-promoting effects of capsaicin are not clear and remain controversial, The Hormel Institute has shown a definite connection to formation of skin cancer through various laboratory studies... (Source: Health News from Medical News Today)
Stereotactic radiosurgery alone for patients with 1?4 radioresistant brain metastases
Abstract Brain metastases from radioresistant histologies are perceived to be less responsive to WBRT compared to other histologies,
and stereotactic radiosurgery (SRS) may provide better local control. The aim of this study was to examine the outcomes of
patients with 1?4 brain metastasis from radioresistant histologies (renal cell carcinoma and melanoma) treated with SRS alone.
Thirty-eight patients with 1?4 radioresistant brain metastases (66 lesions) were treated with SRS alone. The median age was
55 years. Fourteen and 24 patients had renal cell carcinoma (RCC) and melanoma brain metastases, respectively. Distribution
of number of lesions was as follows: one lesion, 22 patients; 2 lesions, 8 patients; 3 lesions, 5 patients; and 4 lesions,
3 patients. Distribu...<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Brachial Plexopathy after Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma
Conclusion:
No radiation-induced brachial plexopathy was seen in the patient group, although 72.1% of the brachial plexuses received doses
> 60 Gy. These findings should prompt further prospective studies and also stress the importance of trying to keep the doses
to the brachial plexus as low as possible while covering the target volumes well.
Content Type Journal ArticleDOI 10.1007/s00066-010-2099-0Authors
Nele Platteaux, Department of Radiation Oncology, Leuvens Kankerinstituut (LKI), University Hospitals Leuven, Campus Gasthuisberg, Leuven, BelgiumPiet Dirix, Department of Radiation Oncology, Leuvens Kankerinstituut (LKI), University Hospitals Leuven, Campus Gasthuisberg, Leuven, BelgiumRobert Hermans, Department of Radiology, Leuvens Kankerinstituut (LKI), ...
Supersize Nutrition With Superfoods
Superfoods won?t give you x-ray vision or invisibility powers, but they may have the power to help fight cancer, heart disease, obesity, and even bad moods.
Duke oncology nutritionist Heidi Scarsella, RD, CSO, LDN, says that while there is no dictionary definition of a superfood, the term refers to foods that are nutrient-dense for their serving size.
?A nutrient-dense food provides substantial amounts of vitamins and minerals and relatively few calories,? she explains.
Some examples include brightly colored fruits and vegetables, whole grains, low-fat and fat-free milk, cheese, and yogurt; and lean meat, poultry, fish, eggs, beans, and nuts.
Standout Superfoods
Click through the slideshow to see some of Scarsella?s favorite superfoods and learn what nutritional benefits you can re...
Capsaicin can act as co-carcinogen, study finds; Chili pepper component linked to skin cancer
New research links capsaicin, a component of chili peppers, to skin cancer. While the molecular mechanisms of the cancer-promoting effects of capsaicin are not clear and remain controversial, the new research has shown a definite connection to formation of skin cancer through various laboratory studies. (Source: ScienceDaily Headlines)
Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma
Background:
The oncogene CDC25B phosphatase plays an important role in cancer cell growth. We have recently reported that patients with esophageal squamous cell carcinoma (ESCC) have significantly higher serum levels of CDC25B autoantibodies (CDC25B-Abs) than both healthy individuals and patients with other types of cancer; however, the potential diagnostic or prognostic significance of CDC25B-Abs is not clear. The aim of this study is to evaluate the clinical significance of serum CDC25B-Abs in patients with ESCC.
Methods:
CDC25B autoantibodies were measured in sera from both 134 patients with primary ESCC and 134 healthy controls using a reverse capture enzyme-linked immunosorbent assay (ELISA) in which anti-CDC25B antibodies bound CDC25B antigen purified from Eca-109 ESCC tumor cells. T...
The surgical importance of an axillary arch in sentinel node biopsy
Conclusions The authors see no reason to deviate from the practice of division of the arch at the highest level when recognised at SNB.
This would abrogate the risk of concealed nodes and possible future neurovascular compression.
Content Type Journal ArticleDOI 10.1007/s00276-010-0724-3Authors
P. F. Ridgway, Department of Surgery, Trinity College Dublin at the Adelaide and Meath Hospital, Tallaght, Dublin 24, IrelandA. M. Collins, Department of Plastic Surgery, St. Vincent?s University Hospital, Dublin, IrelandD. R. McCready, Department of Surgical Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Canada
Journal Surgical and Radiologic AnatomyOnline ISSN 1279-8517Print ISSN 0930-1038 (Source: Surgical and Radiologic Anatomy)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Inhibition of metastasis of syngeneic murine melanoma in vivo and vasculogenesis in vitro by monoclonal antibody C11C1 targeted to domain 5 of high molecular weight kininogen
Abstract Metastasis of malignant tumors is a major cause of morbidity and mortality. Inhibition of tumor growth in distant organs is
of clinical importance. We have demonstrated that C11C1, a murine monoclonal antibody to the light chain region of high molecular
weight kininogen (HK), reduces growth of murine multiple myeloma in normal mice and human colon cancer in nude mice. C11C1
inhibits angiogenesis by reducing tumor microvascular density by blocking binding of HK to endothelial cells. We now evaluate
the anti-metastatic effect of C11C1 on C57BL/6 mouse lung metastatic model using B16F10 melanoma cells. The tail veins of
mice were injected with 0.5 × 106 cells of melanoma B16F10. One group received C11C1 and the other received saline (control) intraperitonea...
XVIth Annual Meeting of Pan American Society for Pigment Cell Research Vancouver Pigmentation and Melanoma Research Conference ?The latest developments in the research and treatment of pigmentation conditions and melanoma?
(Source: Pigment Cell Research)
BRCA1 and BRCA2 families and the risk of skin cancer
Abstract BRCA1 and BRCA2 mutation carriers have elevated risks of breast and ovarian cancers. The risks for cancers at other sites
remain unclear. Melanoma has been associated with BRCA2 mutations in some studies, however, few surveys have included non-melanoma
skin cancer. We followed 2729 women with a BRCA1 or BRCA2 mutation for an average of 5.0 years. These women were asked to
report new cases of cancer diagnosed in themselves or in their family. The risks of skin cancer were compared for probands
with BRCA1 and BRCA2 mutations. Of 1779 women with a BRCA1 mutation, 29 developed skin cancer in the follow-up period (1.6%).
Of the 950 women with a BRCA2 mutation, 28 developed skin cancer (3.0%) (OR = 1.83 for BRCA2 versus BRCA1; 95% CI 1.08?3.10;
P =...
Personal attributions for melanoma risk in melanoma-affected patients and family members
We examined attributions for melanoma risk in a population-based sample of melanoma survivors, first degree family members,
and family members who are also parents (N = 939). We conducted qualitative examination of open-ended risk attributions and logistic regression examining predictors
(demographics, family member type, perceived risk) of the attributions reported (ultraviolet radiation [UVR] exposure, heredity/genetics,
phenotype, personal melanoma history, miscellaneous). We found a predominance of risk attributions to UVR and heredity/genetics
(80 and 45% of the sample, respectively). Those reporting higher education levels were more likely to endorse attributions
to heredity/genetics, as well as to phenotype, than those of lower education levels. First-degree relatives...
Expression of Nur77 induced by an n-butylidenephthalide derivative promotes apoptosis and inhibits cell growth in oral squamous cell carcinoma
Summary In spite of numerous advances, the 5-year survival rate for head and neck squamous cell cancer has remained largely stagnant
and few new anti-tumor drugs have been developed. PCH4, a derivative of n-butylidenephthalide, has been investigated for its
anti-tumor effects on oral squamous cell carcinoma (OSCC). The aim of this study was to investigate the anti-tumor mechanism
of a potential target gene, Nur77, in OSCC cells, which can be induced by PCH4 treatment. Data show that PCH4 promoted Nur77 translocation from the nucleus
to the cytoplasm and induced cell apoptosis in OSCC cells. When Nur77 translocation was blocked, the degree of tumor apoptosis
caused by PCH4 was significantly inhibited (p?<?0.05). Within the MAPK pathway, PCH4 only induced JNK phosphory...<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Spectral to complete development of melanoma detection product this month
Spectral Molecular Imaging, a subsidiary of Cascade Technologies, will complete development of its new product SkinSpect, aimed at early detection of melanoma by hyperspectral imaging, in mid-September, ahead of schedule. (Source: Cardiovascular Business News)
Spectral to complete development of melanoma detection product this month
Spectral Molecular Imaging, a subsidiary of Cascade Technologies, will complete development of its new product SkinSpect, aimed at early detection of melanoma by hyperspectral imaging, in mid-September, ahead of schedule. (Source: Health Imaging News)
Spectral to complete development of melanoma detection product this month
Spectral Molecular Imaging, a subsidiary of Cascade Technologies, will complete development of its new product SkinSpect, aimed at early detection of melanoma by hyperspectral imaging, in mid-September, ahead of schedule. (Source: Health Imaging News)
Hormel Institute study reveals capsaicin can act as cocarcinogen
(University of Minnesota) The September cover story of the nation's leading cancer journal, Cancer Research, features a new study from the Hormel Institute, University of Minnesota, that links capsaicin, a component of chili peppers, to skin cancer. (Source: EurekAlert! - Cancer)
Hypopigmenting Activity of Bisabolangelone Isolated from Angelica koreana Maxim. in ?-Melanocyte Stimulating Hormone-Activated B16 or Melan-a Cells
In this study, roots of Angelica koreana Maxim. (Umbelliferae) inhibited melanin production in α-melanocyte stimulating hormone (α-MSH)-activated B16 melanoma cells or melan-a melanocytes. To elucidate the hypopigmenting principle of A. koreana, the plant extracts were subjected to bioassay-guided phytochemical analysis, resulting in the identification of bisabolangelone. Bisabolangelone dose-dependently inhibited α-MSH-induced melanin production in B16 or melan-a cells with IC50 values of 9–17 µM. The positive control arbutin also inhibited melanin production in B16 cells with an IC50 value of 317 µM. Bisabolangelone suppressed α-MSH-inducible protein levels of tyrosinase in B16 cells but could not significantly inhibit the catalytic activity of ce...<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
A Melanoma Epidemic in Iceland: Possible Influence of Sunbed Use.
Authors: Héry C, Tryggvadóttir L, Sigurdsson T, Olafsdóttir E, Sigurgeirsson B, Jonasson JG, Olafsson JH, Boniol M, Byrnes GB, Doré JF, Autier P
Since 1980, sunbed use and travel abroad have dramatically increased in Iceland (64 degrees -66 degrees N). The authors assessed temporal trends in melanoma incidence by body site in Iceland in relation to sunbed use and travel abroad. Using joinpoint analysis, they calculated estimated annual percent changes (EAPCs) and identified the years during which statistically significant changes in EAPC occurred. Between 1954 and 2006, the largest increase in incidence in men was observed on the trunk (EAPC = 4.6%, 95% confidence interval: 3.2, 6.0). In women, the slow increase in trunk melanoma incidence before 1995 was followed by a sign...
Invited Commentary: A Sunbed Epidemic?
Authors: Berwick M
The Icelandic study of melanoma trends by Héry et al. in this issue of the Journal (Am J Epidemiol. 2010;172(00):000-000) is a fascinating analysis of an ecologic association. The authors noted a sharp increase in melanoma incidence that appeared to lag a few years behind the increased prevalence of sunbeds in Iceland. Caution, however, must be exercised in interpreting the data because of the lack of understanding of emissions of ultraviolet radiation from sunbeds and the ecologic nature of the data.
PMID: 20813800 [PubMed - as supplied by publisher] (Source: Am J Epidemiol)
Half of sun-seeking Britons get sunburnt, despite skin cancer risks
Nearly half of Britons got sunburnt this summer and many would be willing to risk it again in their search for a tan, a survey suggested today. (Source: the Mail online | Health)
Pleural Mesothelioma May Have New Biomarker
In a recent article published in the online publication Modern Pathology, researchers may have found a new biomarker for malignant pleural mesothelioma. They also believe the biomarker may help differentiate malignant mesothelioma from reactive mesothelium.
The biomarker being evaluated is a cell adhesion molecule known as CD146. Previous studies have revealed the molecule?s presence in malignant melanoma, prostate cancer and ovarian cancer. In order to test its diagnostic utility, researchers examined the increased expression of CD146 in malignant pleural mesothelioma and reactive mesothelium using two clones of CD146 antibody on smear specimens of effusion fluids. The two antibodies were OJ79 and EPR3208.
Immunocytochemical stains were measured as zero for negative, one for weak positi...
Half Of Brits Got Sunburnt This Year And Many Would Do It Again
A NEW survey released today (Wednesday 1 September) reveals almost half of Brits (46 per cent) got sunburnt this year. Of those who got burnt, a third (32 per cent) admitted their motivation was to get a tan. And half of those who burnt whilst trying to get a tan would risk burning again next year. The research - commissioned by Superdrug and Cancer Research UK as part of their joint campaign to encourage people to enjoy the sun safely this summer - highlights the worrying lengths sun-seeking Brits are prepared to go to in search of a tan... (Source: Health News from Medical News Today)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Ipilimumab put on fast track by FDA
Ipilimumab has received FDA priority review status, according to Bristol-Myers Squibb. The review will focus on use of the drug in adult patients with previously treated advanced melanoma. (Source: Cancer Network)
Adoptive cell therapy associated with complete, durable regression of melanoma brain metastases
Hong JJ. Clin Cancer Res.
2010;doi:10.1158/1078-0432.CCR-10-1507. (Source: HemOncToday.com)
Sunbathers risk cancer for perfect tan
Sunbathers are putting themselves at risk of developing skin cancer in their pursuit of the perfect tan, a survey has found. (Source: Nursing Times Breaking News)
SG2285, a Novel C2-Aryl-Substituted Pyrrolobenzodiazepine Dimer Prodrug That Cross-links DNA and Exerts Highly Potent Antitumor Activity
The pyrrolobenzodiazepines (PBD) are naturally occurring antitumor antibiotics, and a PBD dimer (SJG-136, SG2000) is in phase II trials. Many potent PBDs contain a C2-endo-exo unsaturated motif associated with the pyrrolo C-ring. The novel compound SG2202 is a PBD dimer containing this motif. SG2285 is a water-soluble prodrug of SG2202 in which two bisulfite groups inactivate the PBD N10-C11 imines. Once the bisulfites are eliminated, the imine moieties can bind covalently in the DNA minor groove, forming an interstrand cross-link. The mean in vitro cytotoxic potency of SG2285 against human tumor cell lines is GI50 20 pmol/L. SG2285 is highly efficient at producing DNA interstrand cross-links in cells, but they form more slowly than those produced by SG2202. Cellular sensitivity to SG2285 ...
Cutaneous Papillomavirus E6 Proteins Must Interact with p300 and Block p53-Mediated Apoptosis for Cellular Immortalization and Tumorigenesis
In this study, we show that the interaction of CRPVE6, or HPV38E6, with the histone acetyltransferase p300 is crucial to inhibit the ability of p53 to induce apoptosis. Strikingly, E6 mutants deficient for p300 binding are incapable of preventing p53 acetylation, p53-dependent transcription, and apoptosis induction. Moreover, E6 mutants deficient for p300 binding cannot contribute to HPV38-induced immortalization of human keratinocytes or CRPV-induced tumor formation. Our findings highlight changes in the p53 acetylation status mediated by the viral E6 protein as a crucial requirement in the ability of high-risk cutaneous papillomaviruses to immortalize primary keratinocytes and induce tumors. Cancer Res; 70(17); 6913–24. ©2010 AACR. (Source: Cancer Research)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Suppression of Casein Kinase 1{alpha} in Melanoma Cells Induces a Switch in {beta}-Catenin Signaling to Promote Metastasis
Casein kinase 1 (CK1) is a multifunctional Ser/Thr kinase that phosphorylates several substrates. Among those is β-catenin, an important player in cell adhesion and Wnt signaling. Phosphorylation of β-catenin by CK1 at Ser45 is the priming reaction for the proteasomal degradation of β-catenin. Interestingly, aside from this role in β-catenin degradation, very little is known about the expression and functional role of CK1 in tumor cells. Here, we show that CK1 expression in different tumor types is either strongly suppressed or completely lost during tumor progression and that CK1 is a key factor determining β-catenin stability and transcriptional activity in tumor cells. CK1 reexpression in metastatic melanoma cells reduces growth in vitro and metastasis formation...
MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.
Authors: Ray S, Chhabra A, Chakraborty NG, Hegde U, Dorsky DI, Chodon T, von Euw E, Comin-Anduix B, Koya RC, Ribas A, Economou JS, Rosenberg SA, Mukherji B,
MHC class I-restricted human melanoma epitope MART-1(27-35) specific TCR-engineered CD4+CD25- T cells synthesize Th1 type cytokines and exhibit cytolytic effector function upon cognate stimulation. A detailed characterization of such TCR-engineered CD4+CD25- T cells now reveals that they are multifunctional. For example, they undergo multiple rounds of division, synthesize cytokines (IFN-gamma, TNF-alpha, IL-2, and MIP1ss), lyse target cells, and "help" the expansion of the MART-1(27-35) specific CD8+ T cells when stimulated by the MART-1(27-35) peptide pulsed DC. Multiparametric analyses reveal that a single TCR-engineered CD4+ T...
Review: Ultraviolet radiation and skin cancer
Abstract (Source: International Journal of Dermatology)
Case report: Positron emission tomography/computed tomography: use for initial staging of malignant melanoma
(Source: International Journal of Dermatology)
Prognostic relevance of Bmi-1 expression and autoantibodies in esophageal squamous cell carcinoma
The objective of this study was to determine the level of Bmi-1 expression or its autoantibodies in human esophageal squamous cell carcinoma (ESCC) and to correlate it with clinicopathologic data.
Methods:
We first examined Bmi-1 expression in ESCC cell lines and tumor samples by RT-PCR and Western blot analysis. We then analyzed Bmi-1 protein expression in 171 clinicopathologically characterized ESCC cases by immunohistochemistry. In addition, we detected its autoantibodies in sera of patients with ESCC by ELISA.
Results:
We found that Bmi-1 expression was higher in the immortalized cells, cancer cell lines and most cancer tissue than in non-tumorous control tissue at both mRNA and protein level. In addition, Bmi-1 expression was observed in 64.3% (110 of 171) archive ESCC specimen by imm...<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Interferon for Melanoma
Anne Marie Lane et al recently reported a study with adjuvant treatment of interferon alfa-2a in 121 patients with choroidal or ciliary body melanoma after proton beam radiation or enucleation. Interferon alfa-2a was administered 3 times per week for a period of 2 years. Eligible for this study were high-risk patients with age ?65, largest tumor diameter ?15 mm, ciliary body involvement of the tumor, extrascleral tumor extension, and diagnosis within 3 years of study enrollment date. The authors show that interferon alfa-2a had no influence on survival in their patients. (Source: Ophthalmology)
Cancer biology: Targeting skin tumours
Nature 467, 8 (2010). doi:10.1038/467008c
N. Engl. J. Med.363, 809–819 (2010) 10.1056/NEJMoa1002011A small clinical trial has shown promising results for a targeted therapy against one of the most aggressive and intractable forms of cancer: metastatic melanoma.The drug, named PLX4032, inhibits a (Source: Nature)
Matrix metalloproteinase?7 activates heparin?binding epidermal growth factor?like growth factor in cutaneous squamous cell carcinoma
(Source: British Journal of Dermatology)
Establishment of a novel human esophageal squamous cell carcinoma cell line (ESC?410) and its partial biological characterization
(Source: Diseases of the Esophagus)
Giant congenital nevi may pose threat of melanoma
If congenital nevi are small, there is insufficient evidence to suggest they should be removed, for
they are not likely to transform into melanoma, according to the chief dermatologist at Phoenix Children's
Hospital, Phoenix. However, giant nevi present a much higher risk, says Ron Hansen, M.D., F.A.A.D., a
board-certified dermatologist and board-certified pediatrician. (Source: Modern Medicine)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Mohs micrographic surgery with MART-1 immunostains targets lentigo maligna
To successfully treat lentigo maligna melanoma and its precursor, lentigo maligna, Mohs micrographic
surgery using MART-1 immunostains is a technique touted by experts, according to David Brodland, M.D., who
practices in Pittsburgh. (Source: Modern Medicine)
Lentigo maligna melanoma, UV light exposure associated, study finds
A study shows for the first time prospectively that chronic ultraviolet (UV) light exposure raises the
risk of lentigo maligna melanoma (LMM), a study co-author says. (Source: Modern Medicine)
Skin cancer recurrence may be prevented with combo of surgery, adjuvant therapies
While surgical and medical oncologists do not think twice about combining treatments such as surgery,
chemotherapy and radiation therapy, in the treatment of cancer patients, dermatologists rarely use adjuvant
therapies once they have excised skin cancers, according to one dermatologist. (Source: Modern Medicine)
Squamous cell carcinoma arising from a localized vulval lesion of Hailey-Hailey disease after tacrolimus therapy
We report a case of HHD affecting exclusively the vulva from which an invasive squamous cell carcinoma developed after tacrolimus therapy. (Source: American Journal of Obstetrics and Gynecology)
CD10?bearing fibroblast inhibits matrigel invasive potency of IL?1??producing squamous cell carcinoma by diminishing substance P levels in tumor microenvironment
(Source: Cancer Science)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Polycyclic aromatic hydrocarbon exposure in oesophageal tissue and risk of oesophageal squamous cell carcinoma in north-eastern Iran.
Authors: Ponder B
PMID: 20804319 [PubMed - in process] (Source: Archives of Iranian Medicine)
Squamous Cell Carcinoma in a Chronic Genital Ulcer in Behçet's Disease.
Authors: Hata H, Aoyagi S, Iitani MM, Homma E, Shimizu H
PMID: 20814642 [PubMed - in process] (Source: Acta Derm Venereol A...)
Skin cancer risk among solid organ recipients: a nationwide cohort study in denmark.
This study assessed the risk of skin cancer following transplantation of 4 types of solid organs, and the risk of skin cancer in patients with chronic diseases that lead to organ transplantations. A population-based cohort of 5279 Danish patients who underwent heart, lung, renal and liver transplantation, and 77,782 patients with chronic heart, lung, renal and liver diseases during 1977-2006 were included in the study. Linkage to the Danish Cancer Registry allowed complete follow-up for basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Standardized incidence ratios (SIR) and 95% confidence intervals (CI) were calculated. The SIR for squamous cell carcinoma was highest among heart (SIR = 113; 95% CI: 74-166), then renal (SIR = 81; 95% CI: 68-96), lung (SIR = 65; 95% CI: ...
Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis (Review).
CONCLUSION: RA may potentiate the risk of cutaneous malignancy and therefore dermatologic screening in this population should be considered. The use of immunomodulatory therapy in RA, psoriasis, and PsA may further increase the risk of cutaneous malignancy and therefore dermatologic screening examinations are warranted in these groups. More careful recording of skin cancer development during clinical trials and cohort studies is necessary to further delineate the risks of immunomodulatory therapy.
PMID: 20810498 [PubMed - as supplied by publisher] (Source: J Rheumatol)
mBeach Software Inc. Extends Global Patent Protection
TEL AVIV, Israel, Aug. 31, 2010 (GLOBE NEWSWIRE) -- mBeach Software Inc. ("MBHS") (OTCBB:MBHS) today announced the filing of additional patent applications under the framework of the Patent Cooperation Treaty (PCT). This move will facilitate the company's strategy to enter new international markets for its advanced, non-invasive system to detect and identify skin cancer. (Source: Medical News (via PRIMEZONE))<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Superficial Spreading Basal Cell Carcinoma of the Face: A Surgical Challenge
The authors report on a 58-year-old white male patient with a case of superficial spreading basal cell carcinoma of the face. ePlasty, Open Access Journal of Plastic Surgery (Source: Medscape Hematology-Oncology Headlines)
Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration With Merck KGaA For Cancer Treatment
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN). Under the terms of the agreement, Idera is entitled to receive a payment of €3... (Source: Health News from Medical News Today)
Key To Melanoma Prediction, Prevention In "Co-Conspirator" Cells
New research on how skin cancer begins has identified adjacent cancer cells that scientists are calling "co-conspirators" in the genesis of melanoma, in findings that could someday hold the key to predicting, preventing and stopping this hard-to-treat cancer before it spreads. Changes in the body's pigment-producing cells, where melanoma - the most dangerous form of skin cancer - takes hold are only part of the story, according to a new study by researchers from Oregon State University... (Source: Health News from Medical News Today)
Plant Agents Show Promise In Preventing Skin Cancer
Maybe you worshipped the sun in your youth or weren't as meticulous as you should have been with sunscreen. If so, take heart: Scientists at The University of Texas Health Science Center San Antonio are finding that certain plant substances, when given in combinations, may suppress damage that can cause skin cancer. The substances, which occur naturally in grapes, berries, walnuts and a number of other plant-based foods, were tested on mice that had been genetically manipulated to be sensitive to skin cancer initiation and promotion/progression... (Source: Health News from Medical News Today)
Chloroform extract from Moricandia arvensis inhibits growth of B16?F0 melanoma cells and promotes differentiation in vitro
Abstract (Source: Cell Proliferation)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Patient understanding of moles and skin cancer, and factors influencing presentation in primary care: a qualitative study
Conclusions:
Changing moles are often perceived as trivial and not signifying possible skin cancer. This study contributes to current national strategies to improve patient awareness and earlier diagnosis of cancer by highlighting factors that can trigger or act as barriers to seeking help.(ISRCTN79932379) (Source: BioMed Central)
Immunoreactivity of integrin-linked kinase in primary non-small-cell lung cancer and survival after curative resection [Original articles]
Conclusions: Primary NSCLC tumours show a variable ILK immunoreactivity, dependent on the histological subtype. In SCC, ILK immunoreactivity is a significantly adverse prognostic factor. (Source: European Journal of Cardio-Thoracic Surgery)
Melanoma Research May Help Colon Cancer Patients
Research on treating metastatic (advanced) melanoma points to an approach that may help colon cancer patients too. A new targeted therapy called PLX4032, also referred to as RG7204, has caused tumors to shrink in 80% of the 81 patients enrolled in two phases of the melanoma study. These results have been published in a recent issue of the New England Journal of Medicine....Read Full Post (Source: About.com Colon Cancer)
Association between Gene Expression Profile, Proliferation and Metastasis in Uveal Melanoma.
Conclusions: On average, class 2 uveal melanomas have a higher proliferative rate than class 1 tumors. Further work is needed to determine whether loss of chromosome 3, increased aneuploidy, or other factors may be responsible for the increased proliferation.
PMID: 20795869 [PubMed - in process] (Source: Current Eye Research)
Women Who Mean Business: Shawn Sabin
Company: Dermatology & Skin Cancer Center (Source: bizjournals.com Health Care:Health Insurance headlines)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Women Who Mean Business: Shawn Sabin
Company: Dermatology & Skin Cancer Center (Source: bizjournals.com Health Care:Biotechnology headlines)
'Co-conspirator' cells could hold key to melanoma prediction, prevention
(Oregon State University) New research on how skin cancer begins has identified adjacent cancer cells that scientists are calling "co-conspirators" in the genesis of melanoma, in findings that could someday hold the key to predicting, preventing and stopping this hard-to-treat cancer before it spreads. (Source: EurekAlert! - Medicine and Health)
Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis
Authors: Karina G Zecchin, Franco A Rossato, Helena F Raposo, Daniela R Melo, Luciane C Alberici, Helena CF Oliveira, Roger F Castilho, Ricardo D Coletta, Aníbal E Vercesi
& Edgard Graner (Source: Laboratory Investigation AOP)
Long Isoforms of NRF1 Contribute to Arsenic-induced Antioxidant Response in Human Keratinocytes
Conclusions: The current study, for the first time, demonstrates that long isoforms of NRF1 contribute to arsenic-induced antioxidant response in human keratinocytes and protect the cells from acute arsenic cytotoxicity. (Source: EHP-in-Press)
[Biological significance of naturally occurring deuterium: the antitumor effect of deuterium depletion.]
Authors: Somlyai G, Molnár M, Laskay G, Szabó M, Berkényi T, Guller I, Kovács A
The concentration of deuterium is about 150 ppm (over 16 mmol/L) in surface water and more than 10 mmol/L in living organisms. Experiments with deuterium depleted water (30+/-5 ppm) revealed that due to D-depletion various tumorous cell lines (PC-3, human prostate, MDA, human breast, HT-29, human colon, M14, human melanoma) required longer time to multiply in vitro . DDW caused tumor regression in xenotransplanted mice (MDA and MCF-7, human breast, PC-3) and induced apoptosis in vitro and in vivo . Deuterium depleted water (25+/-5 ppm) induced complete or partial tumor regression in dogs and cats with spontaneous malignancies, it was registered as anticancer for veterinary use in 1999 (Vetera-DD...<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Spectral Molecular Imaging, Inc. Announces Accelerated Timeline For Its Early Melanoma Detection Product SkinSpect?
Cascade Technologies, Inc. (OTCBB: CSDT) announced today that its wholly-owned subsidiary Spectral Molecular Imaging, Inc. (SMI) will complete development of its new product SkinSpect?, aimed at early detection of melanoma by hyperspectral imaging, in mid-September 2010, significantly ahead of schedule. The device incorporates new advances in component technologies (optics, cameras, displays, embedded computers and software), as well as experience derived from previous prototypes developed under federal funding and tested in the clinic... (Source: Health News from Medical News Today)
A Phase I/II Study of Altered Fractionated IMRT Alone for Intermediate T-Stage Oropharyngeal Carcinoma
Conclusion:
While the routine clinical use of this exploratory schedule is discouraged, it may represent the basis for future developments.
Content Type Journal ArticleDOI 10.1007/s00066-010-2093-6Authors
G. Brandon Gunn, Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX USAEugene J. Endres, Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX USABrent Parker, Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX USAMaria Pia Sormani, Biostatistics Unit, University of Genoa, Genoa, ItalyGiuseppe Sanguineti, Department of Radiation Oncology, University of Texas Medical Branch, Galveston, TX USA
Journal Strahlentherapie und OnkologieOnline ISSN 1439-099XPrint ISSN 0179-...
Clinical Results of Proton-Beam Therapy for Locoregionally Advanced Esophageal Cancer
Conclusion:
The results suggest that proton-beam therapy is an effective treatment for patients with locally advanced esophageal cancer.
Further studies are required to determine the optimal total dose, fractionation schedules, and best combination of proton
therapy with chemotherapy.
Content Type Journal ArticleDOI 10.1007/s00066-010-2079-4Authors
Masashi Mizumoto, Proton Medical Research Center, University of Tsukuba, Ibaraki, JapanShinji Sugahara, Proton Medical Research Center, University of Tsukuba, Ibaraki, JapanHidetsugu Nakayama, Proton Medical Research Center, University of Tsukuba, Ibaraki, JapanHaruko Hashii, Department of Radiation Oncology, University of Tsukuba, Ibaraki, JapanAkira Nakahara, Department of Gastroenterological Medicine, University of T...
Australian Patent Issued To CreAgri® For Ultraviolet Radiation (UVR) Protection By Its Hydroxytyrosol-Based Formulations
CreAgri, Inc.® announced today that the company has received a Patent by the Australian Patent Office, Patent Number 2003249719, which covers the protective effects provided by Hydroxytyrosol against skin damage caused by UV exposure. The patent claims are very broad and include formulations containing the two most important olive polyphenols, Hydroxytyrosol and Oleuropein, whether delivered orally and/or in conjunction with topical applications... (Source: Health News from Medical News Today)
FOXC2 is a Novel Prognostic Factor in Human Esophageal Squamous Cell Carcinoma
Conclusions Our findings suggest that FOXC2 could be an important prognostic indicator for esophageal cancer patients. FOXC2 is directly involved in cancer progression and is associated with poor prognosis in esophageal cancer cases.
Content Type Journal ArticleDOI 10.1245/s10434-010-1274-yAuthors
Naohiro Nishida, Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita JapanKoshi Mimori, Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita JapanTakehiko Yokobori, Department of Surgery and Molecular Oncology, Medical Institute of Bioregulation, Kyushu University, Beppu, Oita JapanTomoya Sudo, Department of Surgery and Molecular Oncology, Medical Institut...<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Sentinel Node Biopsy in Squamous-Cell Carcinoma of the Anal Canal
Conclusions Sentinel node biopsy is a more accurate method than clinical or radiological techniques to stage the disease of patients with
anal carcinoma.
Content Type Journal ArticleDOI 10.1245/s10434-010-1275-xAuthors
Paola De Nardi, Department of Surgery, Scientific Institute San Raffaele Hospital, Milan, ItalyMichele Carvello, Department of Surgery, Scientific Institute San Raffaele Hospital, Milan, ItalyCarla Canevari, Department of Nuclear Medicine, Scientific Institute San Raffaele Hospital, Milan, ItalyPaolo Passoni, Department of Radiotherapy, Scientific Institute San Raffaele Hospital, Milan, ItalyCarlo Staudacher, Department of Surgery, Scientific Institute San Raffaele Hospital, Milan, Italy
Journal Annals of Surgical OncologyOnline ISSN 1534-4681Pr...
Premalignant nature of oral and vulval lichen planus: Facts and controversies
Abstract: Although many classifications include oral lesions of lichen planus in the category of a premalignant condition, there is still much discussion about whether the mucous membranes lesions should be characterized as an intrinsically premalignant condition or merely as a facilitator of the action of a carcinogenic factor. The possibility that an epidermoid carcinoma can emerge at the site of lichen planus lesions, mainly in mucous membranes, has been shown; however, several published cases omit information about other potential risk factors. This prevents a complete analysis of the triggering relationship between lichen planus and squamous cell carcinoma. This contribution reviews the literature on this subject. The question of whether oral or vulval lichen planus, or both, are prem...
Epidemiology: Human papillomavirus?a powerful predictor of survival in patients with oropharyngeal cancer
Epidemiology: Human papillomavirus—a powerful predictor of survival in patients with oropharyngeal cancer
Nature Reviews Clinical Oncology 7, 481 (2010). doi:10.1038/nrclinonc.2010.124
Author: Lisa Richards
Patients with oropharyngeal squamous-cell carcinoma caused by human papillomavirus (HPV) infection have been reported to have a more favorable chance of survival than patients with HPV-negative tumors. However, the prognostic value and clinical significance of this association has, to date, remained undetermined. Now, a study (Source: Nature Clinical Practice Oncology)
Experimental therapies: Vectoring siRNA therapeutics into the clinic
Nature Reviews Clinical Oncology 7, 485 (2010). doi:10.1038/nrclinonc.2010.131
Author: Mauro Ferrari
Nanoparticles are a promising vector-based strategy for the therapeutic administration of small interfering (si)RNA because they protect siRNA from nuclease degradation. A recent phase I study employed transferrin–targeted nanovectors to demonstrate RNA interference mechanisms in a melanoma patient. Multifunctional nanoparticles are providing patient-specific biodistributions of systemically administered siRNA. (Source: Nature Clinical Practice Oncology)
Vaccination with peptides derived from cancer?testis antigens in combination with CpG?7909 elicits strong specific CD8+ T cell response in patients with metastatic esophageal squamous cell carcinoma
(Source: Cancer Science)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Immunoassay for Quantifying Squamous Cell Carcinoma Antigen in Serum [Brief Communications]
CONCLUSIONS:
This SCCa ELISA demonstrates acceptable performance characteristics for quantifying serum SCCa and is effective in eliminating HAMA interference. (Source: Clinical Chemistry)
A novel melanoma-targeting peptide screened by phage display exhibits antitumor activity
Abstract Peptide display on the phage surface has been widely used to identify specific peptides targeting several in vivo and in vitro
tumor cells and the tumor vasculature, playing a role in the discovery of bioactive antitumor agents. Bioactive peptides have
been selected to target important tumor receptors or apoptosis-associated molecules such as p53. Presently, we attempted to
identify potentially antitumor bioactive molecules using the whole cell surface as the recognizable static matrix. Such methodology
could be advantageous in cancer therapy because it does not require previous characterization of target molecules. Using a
C7C phage display library, we screened for peptides binding to the B16F10-Nex2 melanoma cell surface after pre-absorption
on melan-A lineage. ...
Plexxikon Publishes PLX4032 Phase 1 Data Demonstrating 81 Percent Response Rate In Metastatic Melanoma Patients In The New England Journal Of Medicine
Plexxikon today announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. (Source: Pharmaceutical Online News)
Significance of manipulating tumour hypoxia and radiation dose rate in terms of local tumour response and lung metastatic potential, referring to the response of quiescent cell populations.
Authors: Masunaga S, Matsumoto Y, Kashino G, Hirayama R, Liu Y, Tanaka H, Sakurai Y, Suzuki M, Kinashi Y, Maruhashi A, Ono K
The purpose of this study was to evaluate the influence of manipulating intratumour oxygenation status and radiation dose rate on local tumour response and lung metastases following radiotherapy, referring to the response of quiescent cell populations within irradiated tumours. B16-BL6 melanoma tumour-bearing C57BL/6 mice were continuously given 5-bromo-2'-deoxyuridine (BrdU) to label all proliferating (P) cells. They received gamma-ray irradiation at high dose rate (HDR) or reduced dose rate (RDR) following treatment with the acute hypoxia-releasing agent nicotinamide or local hyperthermia at mild temperatures (MTH). Immediately after the irradiation, cells from...
Rho-ROCK-Myosin Signaling Meditates Membrane Type 1 Matrix Metalloproteinase-induced Cellular Aggregation of Keratinocytes [Cell Biology]
Membrane type 1-matrix metalloproteinase (MT1-MMP, MMP14), which is associated with extracellular matrix (ECM) breakdown in squamous cell carcinoma (SCC), promotes tumor formation and epithelial-mesenchymal transition. However, in this report we demonstrate that MT1-MMP, by cleaving the underlying ECM, causes cellular aggregation of keratinocytes and SCC cells. Treatment with an MMP inhibitor abrogated MT1-MMP-induced phenotypic changes, but decreasing E-cadherin expression did not affect MT1-MMP-induced cellular aggregation. As ROCK1/2 can regulate cell-cell and cell-ECM interaction, we examined its role in mediating MT1-MMP-induced phenotypic changes. Blocking ROCK1/2 expression or activity abrogated the cellular aggregation resulting from MT1-MMP expression. Additionally, blocking Rho a...<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
MMP-14 Promotes Keratinocyte Aggregation [Cell Biology]
Membrane type 1-matrix metalloproteinase (MT1-MMP, MMP14), which is associated with extracellular matrix (ECM) breakdown in squamous cell carcinoma (SCC), promotes tumor formation and epithelial-mesenchymal transition. However, in this report we demonstrate that MT1-MMP, by cleaving the underlying ECM, causes cellular aggregation of keratinocytes and SCC cells. Treatment with an MMP inhibitor abrogated MT1-MMP-induced phenotypic changes, but decreasing E-cadherin expression did not affect MT1-MMP-induced cellular aggregation. As ROCK1/2 can regulate cell-cell and cell-ECM interaction, we examined its role in mediating MT1-MMP-induced phenotypic changes. Blocking ROCK1/2 expression or activity abrogated the cellular aggregation resulting from MT1-MMP expression. Additionally, blocking Rho a...
Adenosine and Prostaglandin E2 Cooperate in the Suppression of Immune Responses Mediated by Adaptive Regulatory T Cells [Cell Biology]
Adaptive regulatory T cells (Tr1) are induced in the periphery upon encountering cognate antigens. In cancer, their frequency is increased; however, Tr1-mediated suppression mechanisms are not yet defined. Here, we evaluate the simultaneous involvement of ectonucleotidases (CD39/CD73) and cyclooxygenase 2 (COX-2) in Tr1-mediated suppression. Human Tr1 cells were generated from peripheral blood mononuclear cell-derived, sorted CD4+CD25– T cells and incubated with autologous immature dendritic cells, irradiated COX-2+ or COX-2– tumor cells, and IL-2, IL-10, and IL-15 (each at 10–15 IU/ml) for 10 days as described (Bergmann, C., Strauss, L., Zeidler, R., Lang, S., and Whiteside, T. L. (2007) Cancer Immunol. Immunother. 56, 1429–1442). Tr1 were phenotyped by multicolor ...
Adenosine and PGE2 in Human Treg [Cell Biology]
Adaptive regulatory T cells (Tr1) are induced in the periphery upon encountering cognate antigens. In cancer, their frequency is increased; however, Tr1-mediated suppression mechanisms are not yet defined. Here, we evaluate the simultaneous involvement of ectonucleotidases (CD39/CD73) and cyclooxygenase 2 (COX-2) in Tr1-mediated suppression. Human Tr1 cells were generated from peripheral blood mononuclear cell-derived, sorted CD4+CD25– T cells and incubated with autologous immature dendritic cells, irradiated COX-2+ or COX-2– tumor cells, and IL-2, IL-10, and IL-15 (each at 10–15 IU/ml) for 10 days as described (Bergmann, C., Strauss, L., Zeidler, R., Lang, S., and Whiteside, T. L. (2007) Cancer Immunol. Immunother. 56, 1429–1442). Tr1 were phenotyped by multicolor ...
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. F1000: Ranked "Changes Clinical Practice"
An important new study indicates that oncologists should now consider ipilimumab as a new standard-of-care option for the treatment of metastatic melanoma. Faculty of 1000 Medicine (Source: Medscape Today Headlines)
Matrix Metalloproteinase 9 Targeting Peptides: Syntheses, 68Ga-labeling, and Preliminary Evaluation in a Rat Melanoma Xenograft Model
Bioconjugate Chemistry, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Bioconjugate Chemistry)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Targeted Drug Leads To Regression Of Metastatic Melanoma With Mutated BRAF Gene
Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas, appear in the New England Journal of Medicine... (Source: Health News from Medical News Today)
Microneedle, Quantum Dot Study Opens Door To New Clinical Cancer Tools
Researchers from North Carolina State University have developed extremely small microneedles that can be used to deliver medically-relevant nanoscale dyes called quantum dots into skin - an advance that opens the door to new techniques for diagnosing and treating a variety of medical conditions, including skin cancer. "We were able to fabricate hollow, plastic microneedles using a laser-based rapid-prototyping approach," says Dr. Roger Narayan, one of the lead researchers, "and found that we could deliver a solution containing quantum dots using these microneedles... (Source: Health News from Medical News Today)
Plexxikon Publishes PLX4032 Phase 1 Data Demonstrating 81 Percent Response Rate In Metastatic Melanoma Patients In The New England Journal Of Medicine
Plexxikon announced publication of data from the Phase 1 clinical trial of PLX4032 (RG7204), confirming that treatment of metastatic melanoma patients with the BRAF V600E mutation resulted in significant tumor shrinkage in the majority of patients. Specifically, in the melanoma extension cohort of the study, nearly all patients showed some response; 81 percent of patients had tumor shrinkage of at least 30 percent. The data were published in the August 26, 2010 issue of the New England Journal of Medicine, based on an analysis as of January 31, 2010... (Source: Health News from Medical News Today)
ORIGINAL ARTICLE: Increased expression of peroxiredoxin 6 and cyclophilin A in squamous cell carcinoma of the tongue
(Source: Oral Diseases)
Pill "tackles" skin cancer tumours
A pill helped significantly reduce tumours in the majority of advanced skin cancer patients in a study (Source: Pharmacy Europe)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
LETTER TO THE EDITOR: Malignant melanoma of the breast: N?isopropyl?p?123I?iodoamphetamine single photon emission computed tomography (123I?IMP SPECT) is useful for the detection of metastasis
(Source: The Journal of Dermatology)
Diagnostic value of cancer-testis antigen mRNA in peripheral blood from hepatocellular carcinoma patients.
CONCLUSION: Detecting MAGE-1, SSX-1 and CTp11 mRNA in PBMC improves the total diagnostic rate of HCC.
PMID: 20731022 [PubMed - in process] (Source: World Journal of Gastroenterology : WJG)
Elevated c-Src and c-Yes expression in malignant skin cancers
Conclusions:
c-Src, rather than c-Yes, plays a key role in the proliferation and progression of malignant skin cancers. (Source: Journal of Experimental and Clinical Cancer Research)
Nitric Oxide-Mediated Histone Hyperacetylation in Oral Cancer: Target for a Water-Soluble HAT Inhibitor, CTK7A.
We report here that, unlike in most cancers, histones are found to be highly hyperacetylated in oral squamous cell carcinoma (OSCC; oral cancer) patient samples. Mechanistically, overexpression, as well as enhanced autoacetylation, of p300 induced by nucleophosmin (NPM1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) causes the hyperacetylation, which is nitric oxide (NO) signal dependent. Inhibition of the histone acetyltransferase (HAT) activity of p300 by a water-soluble, small molecule inhibitor, Hydrazinocurcumin (CTK7A), substantially reduced the xenografted oral tumor growth in mice. These results, therefore, not only establish an epigenetic target for oral cancer, but also implicate a HAT inhibitor (HATi) as a potential therapeutic molecule.
PMID: 20797619 [PubMed - as su...
The discovery of the microphthalmia locus and its gene, Mitf.
Authors: Arnheiter H
Summary The history of the discovery of the microphthalmia locus and its gene, now called Mitf, is a testament to the triumph of serendipity. Although the first microphthalmia mutation was discovered among the descendants of a mouse that was irradiated for the purpose of mutagenesis, the mutation most likely was not radiation-induced but occurred spontaneously in one of the parents of a later breeding. Although Mitf might eventually have been identified by other molecular genetic techniques, it was first cloned from a chance transgene insertion at the microphthalmia locus. And although Mitf was found to encode a member of a well-known transcription factor family, its analysis might still be in its infancy had Mitf not turned out to be of crucial importance for the ...<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Surgical versus non-surgical management of early stage oropharyngeal squamous cell carcinoma
This study demonstrates the outcomes of surgical and non-surgical therapy within the same population. Where clear margins
can be achieved, and in the absence of negative prognostic neck pathology, surgery remains a good option; allowing radiotherapy
to be preserved for locoregional failures or second primary tumours. Although there are limitations to this study, it does
demonstrate the benefit of prospective population data collection.
Content Type Journal ArticleDOI 10.1007/s00405-010-1362-4Authors
James O?Hara, Department of Otolaryngology Head and Neck Surgery, The Freeman Hospital, Newcastle upon Tyne, UKKen MacKenzie, Department of Otolaryngology Head and Neck Surgery, Glasgow Royal Infirmary, Glasgow, G31 2ER UK
Journal European Archives of Oto-Rhino-LaryngologyOnl...
Celastrol suppresses invasion of colon and pancreatic cancer cells through the downregulation of expression of CXCR4 chemokine receptor
Abstract Although metastasis accounts for >90% of cancer-related deaths, no therapeutic that targets this process has yet been approved.
Because the chemokine receptor CXCR4 is one of the targets closely linked with tumor metastasis, inhibitors of this receptor
have the potential to abrogate metastasis. In the current report, we demonstrate that celastrol can downregulate the CXCR4
expression on breast cancer MCF-7 cells stably transfected with HER2, an oncogene known to induce the chemokine receptor.
Downregulation of CXCR4 by the triterpenoid was not cell type-specific as downregulation occurred in colon cancer, squamous
cell carcinoma, and pancreatic cancer cells. Decrease in CXCR4 expression was not due to proteolysis as neither proteasome
inhibitors nor lysosomal s...
Health Buzz: Drug Shows Promise Against Melanoma
Organic eggs may not help you avoid salmonella poisoning; new insight on memory care. (Source: U.S. News - Health)
New Hope for Melanoma Patients?
Experimental Drug Shown to Give Many in Trials More Time to Live; Expert: Better Than Chemo, Fewer Side Effects (Source: Health News: CBSNews.com)
New Hope for Melanoma Patients?
Experimental Drug Shown to Give Many in Trials More Time to Live; Expert: Better Than Chemo, Fewer Side Effects (Source: Health News: CBSNews.com)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
New Hope for Melanoma Patients?
Experimental Drug Shown to Give Many in Trials More Time to Live; Expert: Better Than Chemo, Fewer Side Effects (Source: Health News: CBSNews.com)
New Hope for Melanoma Patients?
Experimental Drug Shown to Give Many in Trials More Time to Live; Expert: Better Than Chemo, Fewer Side Effects (Source: Health News: CBSNews.com)
Are antibody deficiency disorders associated with a narrower range of cancers than other forms of immunodeficiency?
Analysis of cancer risk in primary immune deficiency (PID) offers insight into the relationship between immune function and cancer. Data on Australian patients (n = 1132) notified voluntarily to the Australasian Society of Clinical Immunology and Allergy PID Registry (1990-2008) were linked with national death and cancer registries. Person-years of follow-up commenced from up to 15 years before registration on the PID Registry or January 1982, the inception of national cancer registration. Site-specific, 5-year age-, sex-, calendar year–, and state-standardized incidence ratios (SIRs) with 95% confidence intervals (95% CIs) were calculated for all cancers except nonmelanocytic skin cancer. During an average of 16 person-years follow-up, a 1.6-fold excess relative risk of cancer was o...
Video: New Hope for Melanoma Patients
Melanoma is the most dangerous type of skin cancer. Patients in the final stage of the disease have few options but a new drug is offering hope and more time. Sandra Hughes reports. (Source: Health News: CBSNews.com)
Video: New Hope for Melanoma Patients
Melanoma is the most dangerous type of skin cancer. Patients in the final stage of the disease have few options but a new drug is offering hope and more time. Sandra Hughes reports. (Source: Health News: CBSNews.com)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Video: New Hope for Melanoma Patients
Melanoma is the most dangerous type of skin cancer. Patients in the final stage of the disease have few options but a new drug is offering hope and more time. Sandra Hughes reports. (Source: Health News: CBSNews.com)
Video: New Hope for Melanoma Patients
Melanoma is the most dangerous type of skin cancer. Patients in the final stage of the disease have few options but a new drug is offering hope and more time. Sandra Hughes reports. (Source: Health News: CBSNews.com)
Video: New Hope for Melanoma Patients
Melanoma is the most dangerous type of skin cancer. Patients in the final stage of the disease have few options but a new drug is offering hope and more time. Sandra Hughes reports. (Source: Health News: CBSNews.com)
Spectral Molecular Imaging, Inc. Announces Accelerated Timeline for its Early Melanoma Detection Product, SkinSpect
BEVERLY HILLS, Calif.--(Healthcare Sales & Marketing Network)--Cascade Technologies, Inc. (OTCBB: CSDT ) announced today that its wholly-owned subsidiary Spectral Molecular Imaging, Inc. (SMI) will complete development of its new product SkinSpect™, aimed ... Devices, Dermatology, OncologySpectral Molecular Imaging, Cascade Technologies, SkinSpect, melanoma (Source: HSMN NewsFeed)
Experimental targeted cancer drug helps 4 out of 5 metastatic melanoma patients
An experimental anticancer drug that targets a specific genetic mutation benefits 80% of patients with metastatic melanoma, although in some cases the benefit was short-lived, researchers said Wednesday. The results came in a relatively small Phase II... (Source: OrlandoSentinel: Medical Research)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Experimental targeted cancer drug helps 4 out of 5 metastatic melanoma patients [Updated]
An experimental anticancer drug that targets a specific genetic mutation benefits 80% of patients with metastatic melanoma, although in some cases the benefit was short-lived, researchers said Wednesday. The results came in a relatively small Phase II... (Source: OrlandoSentinel: Medical Research)
Plexxikon Publishes PLX4032 Phase 1 Data Demonstrating 81 Percent Response Rate in Metastatic Melanoma Patients in the New England Journal of Medicine
BERKELEY, Calif.--(BUSINESS WIRE)--Aug 25, 2010 - Plexxikon
today announced publication of data from the Phase 1 clinical trial
of PLX4032 (RG7204), confirming that treatment of metastatic
melanoma patients with the BRAF V600E mutation... (Source: Drugs.com - Clinical Trials)
Penn Study Makes Breakthrough In Shrinking Tumors of Terminal Melanoma Patients
Penn Study Makes Breakthrough In Shrinking Tumors of Terminal
Melanoma Patients [The Philadelphia Inquirer]
From Philadelphia Inquirer (PA) (August 26, 2010)
Aug. 26--In a major advance against the deadliest type of skin
cancer, a genetically... (Source: Drugs.com - Pharma News)
New Hope for Melanoma Patients?
Experimental Drug Shown to Give Many in Trials More Time to Live; Expert: Better Than Chemo, Fewer Side Effects (Source: Health News: CBSNews.com)
Polycyclic aromatic hydrocarbon exposure in oesophageal tissue and risk of oesophageal squamous cell carcinoma in north-eastern Iran
Conclusions
Dramatically higher levels of 8E11 staining were observed in non-tumoral oesophageal epithelium from patients with ESCC than from control subjects. This finding strengthens the evidence for a causal role for PAHs in oesophageal carcinogenesis in north-eastern Iran. (Source: Gut)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
The role of CIP2A in oral squamous cell carcinoma.
Authors: Basile JR, Czerninski R
PMID: 20729627 [PubMed - as supplied by publisher] (Source: Cancer Biology and Therapy)
Multiple cutaneous squamous cell carcinomas in a patient with interferon {gamma} receptor 2 (IFN{gamma}R2) deficiency
Disseminated squamous cell carcinoma (SCC) of the skin is exceedingly rare in children. SCC occurs after immunodeficiency from immunosuppression in organ transplant recipients or patients with HIV infection or leukaemia, but has not been reported in primary immunodeficiencies other than epidermodysplasia verruciformis. Interferon receptor 2 (IFNR2) deficiency is an exceedingly rare primary immunodeficiency, conferring almost selective predisposition to mycobacterial diseases. A disseminated, cutaneous SCC is described that occurred in a patient homozygous for a novel frameshift deletion at positions 949 and 950 (949delTG) in the IFNGR2 gene. The patient first presented at 1 year of age with disseminated Mycobacterium avium infection, with later infections of atypical mycobacteria (Myc...
Oesophageal squamous cell carcinoma in a young adult with IL-12R{beta}1 deficiency
We report three relatives with IL-12Rβ1 deficiency. At the age of 25 years old, one patient presented with oesophageal squamous cell carcinoma (OSCC). The patient had no previous risk factors for OSCC. He died at the age of 29 years. OSCC is exceedingly rare in individuals under 30 years and frequently relates to alcohol intake and smoking. Disorders of the IL-12-IL-23/IFN- axis may predispose to cancer. (Source: Journal of Medical Genetics)
Advanced melanoma: New targeted therapy successful in more than 80 percent of patients
Use of an experimental targeted drug to treat metastatic melanoma tumors with a specific genetic signature was successful in more than 80 percent of patients in a phase 1 clinical trial. Results of the trial of PLX4032, an inhibitor of a protein called BRAF that is overactive in more than half of all melanomas, appear in a new study. (Source: ScienceDaily Headlines)
New Targeted Therapy For Advanced Melanoma Associated With 80% Response Rate
A multicenter study has concluded that treatment with a new targeted therapy called PLX4032 (also called RG7204) resulted in significant tumor shrinkage in 80 percent of patients with advanced melanoma. Investigators at Memorial Sloan-Kettering Cancer Center and colleagues at other cancer centers have published their findings in the August 26 edition of the New England Journal of Medicine. "Metastatic melanoma is a very challenging disease to treat and there have been no significant therapeutic advances in the past 20 years... (Source: Health News from Medical News Today)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Experimental Drug That Targets BRAF Cancer Gene Shows Promise Against Metastatic Melanoma
A phase 1 clinical trial using a new formulation of an experimental drug that targets the BRAF cancer gene, has shown early promise in treating melanoma in patients with a mutated form of the gene and whose skin cancer has progressed to the metastatic stage. A paper on the trial appears in the 26 August issue of the New England Journal of Medicine, NEJM... (Source: Health News from Medical News Today)
New Drug May Treat Advanced Melanoma
Title: New Drug May Treat Advanced MelanomaCategory: Health NewsCreated: 8/26/2010 11:04:00 AMLast Editorial Review: 8/26/2010 11:04:24 AM (Source: MedicineNet Cancer General)
In Early Trial, Targeted Therapy Fights Advanced Melanoma
Title: In Early Trial, Targeted Therapy Fights Advanced MelanomaCategory: Health NewsCreated: 8/25/2010 6:10:00 PMLast Editorial Review: 8/26/2010 (Source: MedicineNet Cancer General)
New Drug May Treat Advanced Melanoma
Title: New Drug May Treat Advanced MelanomaCategory: Health NewsCreated: 8/26/2010 11:04:00 AMLast Editorial Review: 8/26/2010 11:04:24 AM (Source: MedicineNet Skin General)
In Early Trial, Targeted Therapy Fights Advanced Melanoma
Title: In Early Trial, Targeted Therapy Fights Advanced MelanomaCategory: Health NewsCreated: 8/25/2010 6:10:00 PMLast Editorial Review: 8/26/2010 (Source: MedicineNet Skin General)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Drug May Treat Advanced Melanoma
New Drug May Treat Advanced Melanoma (Source: eMedicineHealth.com)
Dramatic results for skin cancer pill
A pill for advanced skin cancer that targets patients with particular genetic make-up had dramatic results, scientists revealed. (Source: The Independent - Science)
A step toward a new sunscreen?
(University of Texas Health Science Center at San Antonio) Ongoing research finds that a blend of plant substances -- such as resveratrol and grape seed extract -- can prevent skin cancer in mice. (Source: EurekAlert! - Medicine and Health)
Targeted Therapy Shows Early Promise in Melanoma (CME/CE)
(MedPage Today) -- A novel drug targeted to a common mutation behind melanoma appears effective in skin tumors that carry the mutation, according to early results. (Source: MedPage Today Dermatology)
'Breakthrough' melanoma drug shrinks tumors
Scientists say the experimental drug could revolutionize treatment of advanced melanoma, which can kill within nine months of diagnosis. (Source: USATODAY.com Health)<div id="medworm"><p><b><i>MedWorm Message:</i></b> Register for <b><a href="http://www.medmatcha.com" target ="_self">MedMatcha, MedWorm's medical advertising network</a></b>, and receive $5 free advertising.</p></div>
Breakthrough hopes as pill reduces tumours in four out of five patients
A PILL for advanced skin cancer that targets patients with a particular genetic make-up has had dramatic results. (Source: Scotsman.com News - Health)
Doctors encouraged by melanoma drug
BOSTON, Aug. 25 (UPI) -- An experimental drug treatment for advanced melanoma, a disease that often kills sufferers within nine months, has encouraged medical professionals, they say.
Melanoma - Health - Medicine - Experimental drug - United States (Source: Health News - UPI.com)
New Drug May Treat Advanced Melanoma
A new drug that fights tumors throughout the bodies of advanced melanoma patients points the way to powerful new treatments for many kinds of cancer. (Source: WebMD Health)
Inter-observer variability of teledermoscopy- an international study.
Conclusions: There was good agreement amongst dermatologists A-D but dermatologist E varied from the group with more frequent diagnosis of melanoma and atypical naevus. This difference could be due to different definition of terms with lack of consensus guidelines in definition of atypical naevus, lack of familiarity with the specific patient population and/or diagnostic drift.
PMID: 20795998 [PubMed - as supplied by publisher] (Source: The British Journal of Dermatology)
mesothelioma attorney by asking your doctor. A good place to look for a successful mesothelioma attorney is by looking on the web, there are many different Texas mesothelioma lawyers that have their own Internet sites.
Why choose Texas mesothelioma attorneys? It doesn't matter what area of the state you live in. Whether you are in northern Texas or live in Beaumont you will need a Beaumont mesothelioma attorney or a Special Texas mesothelioma attorney who can represent you well. You should also want to promote mesothelioma awareness while at the same time get the compensation you need so much. After all we don't want to see another mesothelioma victim 40 years down the road, and that is the true point to the mesothelioma case.
Taking care of yourself is the #1 priority when you've been exposed to cancer causing materials. Finding Texas mesothelioma lawyers who can represent you and your family is an important choice. Texas mesothelioma lawyers can see to it you get the information about your options, please visit www.mesothelioma-center-inc.com.
|
